Psyence Biomedical Ltd. Common Shares Total Liabilities
Psyence Biomedical Ltd. Common Shares total liabilities. Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has total liabilities worth $943.07K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Psyence Biomedical Ltd. Common Shares liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Psyence Biomedical Ltd. Common Shares (2021–2025)
Total liabilities of Psyence Biomedical Ltd. Common Shares from 2021 to 2025. This chart illustrates how Psyence Biomedical Ltd. Common Shares's total liabilities have evolved over time, based on quarterly financial data. Explore PBM strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Psyence Biomedical Ltd. Common Shares Competitors by Total Liabilities
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vaxtex Cotfab Limited
NSE:VCL
|
India | Rs143.82 Million |
|
Ecobuilt Holdings Bhd
KLSE:0059
|
Malaysia | RM89.28 Million |
|
Bubalus Resources Ltd
AU:BUS
|
Australia | AU$122.42K |
|
Mingteng International Corporation Inc. Ordinary Shares
NASDAQ:MTEN
|
USA | $9.20 Million |
|
Birddog Technology Ltd
AU:BDT
|
Australia | AU$2.15 Million |
|
Thai Mui Corporation Public Company Limited
BK:THMUI
|
Thailand | ฿268.40 Million |
|
Madhav Marbles and Granites Limited
NSE:MADHAV
|
India | Rs190.93 Million |
|
Haffner Energy SA
PA:ALHAF
|
France | €14.12 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Psyence Biomedical Ltd. Common Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Psyence Biomedical Ltd. Common Shares assets under control.
Liquidity & Leverage Metrics
Psyence Biomedical Ltd. Common Shares Total Liabilities Ratios Explained
Psyence Biomedical Ltd. Common Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Psyence Biomedical Ltd. Common Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Psyence Biomedical Ltd. Common Shares (2021–2025)
The table below shows the annual total liabilities of Psyence Biomedical Ltd. Common Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $594.37K | -95.09% |
| 2024-03-31 | $12.10 Million | -15.18% |
| 2023-03-31 | $14.27 Million | -12.87% |
| 2022-03-31 | $16.38 Million | +16104.79% |
| 2021-03-31 | $101.08K | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more